Here, we explain a pharmacogenetics tactic that permits to selectively and reversibly inactivate LC neurons applying Designer Receptors Exclusively Activated by Designer Medicine (DREADD). We clearly show that the expression of the hM4Di DREADD is often restricted to noradrenergic LC neurons and that the quantity of LC inhibition could be adjusted